Is CINQAIR Right for Your Patient?

Consider which patients in your practice may benefit from CINQAIR

Consider CINQAIR for patients 18 years of age and older with:

  • Blood eosinophil count of ≥400 cells/mcL* within 3 to 4 weeks of dosing or other symptoms of an eosinophilic phenotype1
  • Severe asthma that is inadequately controlled despite standard of care (medium- to high-dose inhaled corticosteroids with long-acting beta agonists)2,3
    • Symptoms >2 days a week
    • Short-acting beta agonist use for symptom control >2 days a week
    • Interference with daily activities
  • At least 1 asthma exacerbation requiring use of oral (systemic) corticosteroids over the last 12 months1
  • Compromised lung function (FEV1 <80% predicted)2,3

This eosinophil level represents the population in Studies I, II, and III.

Test your patients’ blood eosinophil levels

Consider ordering a complete blood count (CBC) with differential diagnosis for your patients with severe asthma.4

TEVA SUPPORT SOLUTIONS®

Access & Affordability

Get Started

Training & Education

Learn More

Product Acquisition

Find a Distributor

INDICATIONS AND USAGE

CINQAIR is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

Limitations of Use:  CINQAIR is not indicated for:

  • treatment of other eosinophilic conditions
  • relief of acute bronchospasm or status asthmaticus

IMPORTANT SAFETY INFORMATION WARNING: ANAPHYLAXIS

  • Anaphylaxis has been observed with CINQAIR infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of CINQAIR.
  • Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after CINQAIR administration by a healthcare professional prepared to manage anaphylaxis. Discontinue CINQAIR immediately if the patient experiences signs or symptoms of anaphylaxis.

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

  • CINQAIR is contraindicated in patients who have known hypersensitivity to reslizumab or any of its excipients.

WARNINGS AND PRECAUTIONS

  • Acute Asthma Symptoms or Deteriorating Disease: CINQAIR should not be used to treat acute asthma s